{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '8', 'STUDY OBJECTIVES', 'The overall objective is to evaluate the safety and efficacy of teprotumumab in the treatment of', 'TED in subjects who participated in the lead-in study (HZNP-TEP-301) and who were either', 'proptosis non-responders at Week 24 of HZNP-TEP-301 or were proptosis responders at', 'Week 24 but meet the criteria for re-treatment due to relapse (see Section 9.3.4) during the', 'Follow-Up Period of HZNP-TEP-301.', '8.1', 'Primary Objective', 'The primary objective is to evaluate the effect of teprotumumab on the proptosis responder rate', '(i.e., the percentage of subjects with a > 2 mm reduction from Baseline in the study eye without', 'deterioration 1> 2 mm increase] of proptosis in the fellow eye) at Week 24.', '8.2', 'Secondary Objectives', 'Secondary objectives will evaluate the effect of teprotumumab on the following:', '1. Percentage of subjects with a Clinical Activity Score (CAS) value of 0 or 1 at Week 24 in', 'the study eye.', '2. Mean change from Baseline to Week 24 in proptosis measurement in the study eye.', '3. Diplopia responder rate (i.e., the percentage of subjects with baseline diplopia > 0 in study', 'eye who have a reduction of > 1 grade with no corresponding deterioration [> 1 grade', 'worsening] in the fellow eye) at Week 24.', \"4. Mean change from Baseline to Week 24 in the Graves' Ophthalmopathy Quality of Life\", '(GO-QoL) questionnaire overall score.', '8.3', 'Exploratory Objectives', 'Exploratory objectives will evaluate the effect of teprotumumab on the following:', '1. The overall responder rate (percentage of subjects with > 2-point reduction in CAS AND', '> 2 mm reduction in proptosis from Baseline, provided there is no corresponding', 'deterioration [>2 point/mm increase] in CAS or proptosis in the fellow eye) at Week 24.', '2. Clinical Measures of Severity individual response status frequencies and percentage of', 'responders for each component of clinical severity at Week 24.', '3. Mean change from Baseline to Week 24 in the CAS.', '4.', 'Overall responder rate at Week 24 stratified by the level of response (high responders,', 'responders, low responders, and non-responders; see Section 9.6.3.2.1 for definitions).', '5. Mean change from Baseline to Week 24 in the GO-QoL questionnaire visual functioning', '(VF) and appearance (A) subscale scores.', '6. Mean change from Baseline to Week 24 on the motility component of the Clinical', 'Measures of Severity.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 68 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '7. Evaluate pharmacokinetic (PK) parameters of teprotumumab to estimate exposure and', 'understand PK-PD relationships.', '9', 'INVESTIGATIONAL PLAN', '9.1', 'Overall Study Design and Plan', 'This study will be conducted at up to 16 sites in the United States and Europe.', 'This is a multi-center, open-label extension study of HZNP-TEP-301 examining the safety and', 'efficacy of teprotumumab in the treatment of TED in adult subjects. Subjects who complete the', '24-week double-masked Treatment Period in Study HZNP-TEP-301 and are proptosis', 'non-responders or were proptosis responders at Week 24 but meet the criteria for re-treatment', 'due to relapse (see Section 9.3.4) during the Follow-Up Period of HZNP-TEP-301 will be', 'eligible for enrollment. The study treatment previously administered in HZNP-TEP-301', '(teprotumumab or placebo) will remain masked throughout this extension study.', 'All subjects who choose to participate will receive 8 infusions of teprotumumab (10 mg/kg for', 'the first infusion followed by 20 mg/kg for the remaining 7 infusions) in an open-label fashion.', 'The Baseline (Day 1) Visit of this extension study will occur within 14 days after the final visit', 'of Study HZNP-TEP-301 (Week 24 for proptosis non-responders and up to Week 72 for subjects', 'who relapse). During the open-label Treatment Period, study drug infusions are scheduled for', 'Day 1 (Baseline), and Weeks 3, 6, 9, 12, 15, 18, and 21 (with a final visit at Week 24 of the', '24-Week Treatment Period).', 'All study drug dosing will be performed at the clinic under the supervision of clinic staff, and at', 'any scheduled infusion, the infusion rate may be reduced or the dose may be interrupted or held', 'based on decreased tolerability (see Section 9.4.6.3.2 for details). On each dosing day, scheduled', 'assessments (except for adverse event [AE] and concomitant medication use monitoring, which', 'will be monitored throughout the clinic visit) will be completed prior to study drug dosing. After', 'each of the first 2 infusions, subjects will be contacted by phone/email the following day and will', 'return to the clinic 1 week after the infusion (Weeks 1 and 4) for safety and tolerability', 'assessments; additional phone/email contacts and clinic visits may also be conducted for any', 'subject experiencing an infusion-associated event.', 'After completion of the Treatment Period, subjects who were proptosis non-responders in', 'Study HZNP-TEP-301 will enter a 24-week Follow-Up Period, during which study drug will not', 'be administered and clinic visits are scheduled for 1, 3, and 6 months (visit months 7, 9, and 12)', 'after the Week 24 Visit; if any of these subjects discontinue from the Follow-Up Period prior to', 'the Month 12 Visit, they will return to the clinic and undergo the scheduled Month 12', 'assessments prior to study discharge. Those who complete the Month 12 Visit will be contacted', '6 and 12 months later via phone or email by research staff to enquire if any treatment for TED', 'has been received since last study contact. If yes, subject will be questioned regarding type of', 'treatment and outcome/response.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 69 of 118']\n\n###\n\n", "completion": "END"}